Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 11/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6799690 | 0.74 | ALDH1A1 (0.44) | ALDH1A1MAPTMEN1MAPK1KMT2A | |
| SCHEMBL4667707 | 0.74 | BCAT2 (0.42) | ALDH1A1MAPTMEN1MAPK1KMT2A | |
| SCHEMBL15468336 | 0.72 | ALDH1A1 (0.53) | ALDH1A1MAPTMEN1MAPK1KMT2A | |
| SCHEMBL4667152 | 0.70 | BCAT2 (0.42) | ALDH1A1MAPTMEN1KMT2AHSD17B10 | |
| SCHEMBL3641807 | 0.69 | MEN1 (0.50) | ALDH1A1MAPTMEN1MAPK1KMT2A | |
| SCHEMBL4667274 | 0.68 | ALOX5 (0.33) | ALDH1A1MAPTMEN1MAPK1KMT2A | |
| SCHEMBL27213298 | 0.67 | MAPT (0.47) | ALDH1A1MAPTMEN1MAPK1KMT2A | |
| SCHEMBL31689136 | 0.67 | MAPK8 (0.55) | ALDH1A1MAPTMEN1MAPK1KMT2A | |
| SCHEMBL5067843 | 0.67 | — | — | |
| SCHEMBL13147514 | 0.66 | NPC1 (0.58) | ALDH1A1MAPTMEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287493-A1 | ARYLMETHYLEN SUBSTITUTED N-ACYL-Y-AMINOALCOHOLS | BAYER SCHERING PHARMA AG (DE) | 2008-11-20 | — | — | US | claimed |
| WO-2008131972-A1 | ARYLMETHYLEN SUBSTITUTED N-ACYL-GAMMA-AMINOALCOHOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-06 | — | — | WO | claimed |
| EP-1985612-A1 | Arymethylen substituted N-Acyl-gamma-aminoalcohols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-10-29 | — | — | EP | claimed |
| US-20080287493-A1 | ARYLMETHYLEN SUBSTITUTED N-ACYL-Y-AMINOALCOHOLS | BAYER SCHERING PHARMA AG (DE) | 2008-11-20 | — | — | US | disclosed |
| WO-2008131972-A1 | ARYLMETHYLEN SUBSTITUTED N-ACYL-GAMMA-AMINOALCOHOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-06 | — | — | WO | disclosed |
| EP-1985612-A1 | Arymethylen substituted N-Acyl-gamma-aminoalcohols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287493-A1 | ARYLMETHYLEN SUBSTITUTED N-ACYL-Y-AMINOALCOHOLS | FSHR, CYP19A1, GNRHR | ALDH1A1 1026/4885MAPT 4844/4885MEN1 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.